Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/214060
Title: | Safety and effectiveness of isavuconazole in real-life non-neutropenic patients |
Author: | Monzó-gallo, Patricia Lopera, Carlos Badía-tejero, Ana M Machado, Marina García-rodríguez, Julio Vidal-cortés, Pablo Merino, Esperanza Calderón, Jorge Fortún, Jesús Palacios-baena, Zaira R. Pemán, Javier Sanchis, Joan Roig Aguilar-guisado, Manuela Gudiol, Carlota Ramos, Juan C Sánchez-romero, Isabel Martin-davila, Pilar López-cortés, Luis E. Salavert, Miguel Ruiz-camps, Isabel Chumbita, Mariana Aiello, Tommaso Francesco Peyrony, Olivier Puerta-alcalde, Pedro Soriano, Alex Marco, Francesc Garcia-vidal, Carolina |
Issue Date: | 1-Jul-2024 |
Publisher: | Elsevier BV |
Abstract: | Objectives: Information is scarce on clinical experiences with non-neutropenic patients with invasive fungal infection (IFI) receiving isavuconazole. We aimed to report the safety and effectiveness of this drug as a first-line treatment or rescue in real life. Methods: A retrospective, observational multicentric study of non-neutropenic patients who received isavuconazole as an IFI treatment at 12 different university hospitals (January 2018-2022). All patients met criteria for proven, probable or possible IFI according to EORTC-MSG. Results: A total of 238 IFIs were treated with isavuconazole during the study period. Combination therapy was administered in 27.7% of cases. The primary IFI was aspergillosis (217, 91.2%). Other IFIs treated with isavuconazole were candidemia (n = 10), mucormycosis (n = 8), histoplasmosis (n = 2), cryptococcosis (n = 2), and others (n = 4). Median time of isavuconazole treatment was 29 days. Only 5.9% (n = 14) of cases developed toxicity, mainly hepatic-related (10 patients, 4.2%). Nine patients (3.8%) had treatment withdrawn. Successful clinical response at 12 weeks was documented in 50.5% of patients. Conclusion: Isavuconazole is an adequate treatment for non-neutropenic patients with IFIs. Toxicity rates were low and its effectiveness was comparable to other antifungal therapies previously reported. (c) 2024 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. This is an open access article under the CC BY-NC-ND license ( http://creativecommons.org/licenses/by-nc-nd/4.0/ ) |
Note: | Reproducció del document publicat a: https://doi.org/10.1016/j.ijid.2024.107070 |
It is part of: | International Journal of Infectious Diseases, 2024, vol. 144, p. 107070 |
URI: | http://hdl.handle.net/2445/214060 |
Related resource: | https://doi.org/10.1016/j.ijid.2024.107070 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
PIIS1201971224001413.pdf | 387.27 kB | Adobe PDF | View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.